Literature DB >> 3325254

Development of resistance to ofloxacin.

G C Crumplin1, M Odell.   

Abstract

As a member of the 4-quinolone group of antibacterial agents, ofloxacin shares the almost unique feature of being exempt from plasmid-borne resistance in either Gram-negative or Gram-positive bacteria. In the light of this feature, the development of resistance mediated through chromosomal mutation has been carefully studied, particularly the processes of mutation which confer resistance to levels of ofloxacin approaching those obtained at the site of infection after oral administration. With Escherichia coli strain KL16 being used as a model system, the genetics of the development of resistance to ofloxacin at least 2 mg/L have been studied. In common with many in vitro studies of the development of resistance to the newer 4-quinolones, it has been observed that the mutation frequency was extremely low (in the range 1 X 10(-10) to 1 X 10(-12) with bacteria grown under routine laboratory conditions. The resultant organisms were very slow growing, temperature sensitive and apparently auxotrophic. The mutation(s) were, however, very unstable and the mutants readily reverted to ofloxacin sensitivity in the absence of selection with ofloxacin. Subsequent studies of spontaneous mutation under growth conditions more closely related to the in vivo situation in the lumen of the gut, with limitation of oxygen supply, showed that mutation frequencies were in the order of 1 X 10(-8). Mutants obtained under these conditions displayed the same phenotype as found previously and were equally unstable. Examination of the physiology of the ofloxacin-resistant mutants has shown that they display significant metabolic defects with regard to being able to cope with environmental fluctuations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3325254     DOI: 10.2165/00003495-198700341-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  14 in total

1.  Apparent absence of transferable resistance to nalidixic acid in pathogenic Gram-negative bacteria.

Authors:  L G Burman
Journal:  J Antimicrob Chemother       Date:  1977-09       Impact factor: 5.790

2.  Nalidixic acd-resistant mutants of Escherichia coli deficient in isocitrate dehydrogenase.

Authors:  R B Helling; J S Kukora
Journal:  J Bacteriol       Date:  1971-03       Impact factor: 3.490

3.  Genetic and physiological analysis of an envB spherelike mutant of Escherichia coli K-12 and characterization of its transductants.

Authors:  B Westling-Häggström; S Normark
Journal:  J Bacteriol       Date:  1975-07       Impact factor: 3.490

Review 4.  Biology of bacterial deoxyribonucleic acid topoisomerases.

Authors:  K Drlica
Journal:  Microbiol Rev       Date:  1984-12

5.  New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity.

Authors:  J Yamagishi; Y Furutani; S Inoue; T Ohue; S Nakamura; M Shimizu
Journal:  J Bacteriol       Date:  1981-11       Impact factor: 3.490

6.  Regulation of the genes for E. coli DNA gyrase: homeostatic control of DNA supercoiling.

Authors:  R Menzel; M Gellert
Journal:  Cell       Date:  1983-08       Impact factor: 41.582

7.  Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

Authors:  S Inoue; T Ohue; J Yamagishi; S Nakamura; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

8.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

9.  Mutation affecting resistance of Escherichia coli K12 to nalidixic acid.

Authors:  J Hrebenda; H Heleszko; K Brzostek; J Bielecki
Journal:  J Gen Microbiol       Date:  1985-09

10.  Nalidixic acid-resistant auxotrophs of Escherichia coli.

Authors:  R B Helling; B S Adams
Journal:  J Bacteriol       Date:  1970-11       Impact factor: 3.490

View more
  9 in total

Review 1.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

Review 2.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

3.  Novel and Structurally Diversified Bacterial DNA Gyrase Inhibitors Discovered through a Fluorescence-Based High-Throughput Screening Assay.

Authors:  Eddy E Alfonso; Zifang Deng; Daniel Boaretto; Becky L Hood; Stefan Vasile; Layton H Smith; Jeremy W Chambers; Prem Chapagain; Fenfei Leng
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-02

4.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

5.  Ofloxacin compared with chloramphenicol in the management of external ocular infection.

Authors:  A J Bron; G Leber; S N Rizk; H Baig; A R Elkington; G R Kirkby; C Neoh; A Harden; T Leong
Journal:  Br J Ophthalmol       Date:  1991-11       Impact factor: 4.638

6.  Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy.

Authors:  R H Liang; R W Yung; T K Chan; P Y Chau; W K Lam; S Y So; D Todd
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

7.  Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group.

Authors:  A Gwon
Journal:  Br J Ophthalmol       Date:  1992-12       Impact factor: 4.638

8.  Quinolone resistance: much more than predicted.

Authors:  Alvaro Hernández; María B Sánchez; José L Martínez
Journal:  Front Microbiol       Date:  2011-02-11       Impact factor: 5.640

9.  Non-clinical isolates as potential reservoirs of antibiotic resistance in Port Harcourt, Nigeria.

Authors:  Kome Otokunefor; Paul Agbude; Tosanwumi Vincent Otokunefor
Journal:  Pan Afr Med J       Date:  2018-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.